These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 24461476

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L.
    Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
    [Abstract] [Full Text] [Related]

  • 5. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M, Heikman P, Ojanperä I.
    Forensic Sci Int; 2013 Oct 10; 232(1-3):11-5. PubMed ID: 24053859
    [Abstract] [Full Text] [Related]

  • 6. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.
    Med J Aust; 2009 Aug 03; 191(3):161-5. PubMed ID: 19645647
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR, Lea T, Sheridan J.
    Int J Drug Policy; 2008 Dec 03; 19(6):450-8. PubMed ID: 18359216
    [Abstract] [Full Text] [Related]

  • 8. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF, Black RA, Severtson SG, Dart RC, Green JL.
    J Subst Abuse Treat; 2018 Jan 03; 84():42-49. PubMed ID: 29195592
    [Abstract] [Full Text] [Related]

  • 9. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW, Hjelmström P, Sumner M, 006 Study Investigators.
    Clin Ther; 2015 Oct 01; 37(10):2244-55. PubMed ID: 26412801
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.
    Addiction; 2012 Jan 01; 107(1):142-51. PubMed ID: 21749526
    [Abstract] [Full Text] [Related]

  • 11. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
    Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC.
    Drug Alcohol Depend; 2010 Sep 01; 111(1-2):44-9. PubMed ID: 20478668
    [Abstract] [Full Text] [Related]

  • 12. Abuse and diversion of buprenorphine sublingual tablets and film.
    Lavonas EJ, Severtson SG, Martinez EM, Bucher-Bartelson B, Le Lait MC, Green JL, Murrelle LE, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC.
    J Subst Abuse Treat; 2014 Jul 01; 47(1):27-34. PubMed ID: 24680219
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.
    White N, Flaherty I, Higgs P, Larance B, Nielsen S, Degenhardt L, Ali R, Lintzeris N.
    Drug Alcohol Rev; 2015 Nov 01; 34(6):623-9. PubMed ID: 26179339
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M, Mundin G, Sumner M.
    Eur J Pharm Sci; 2018 Sep 15; 122():125-133. PubMed ID: 29940217
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone-experience from a medium-sized Finnish city.
    Uosukainen H, Pentikäinen H, Tacke U.
    J Subst Abuse Treat; 2013 Jul 15; 45(1):143-7. PubMed ID: 23433750
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.
    Int J Drug Policy; 2011 Mar 15; 22(2):167-71. PubMed ID: 21112758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.